Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced new strategic partnerships with the Agency for Science, Technology, and Research

Olon, a pharmaceutical manufacturer and global CDMO company, confirms the timeline for the construction of its new high potency API manufacturing facility in Rodano (Milan) and confirms that the installation and validation of the new small-scale production area within the facility has already been successfully completed.

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica.

Geneial, a company advancing private, community-led genetic medicine, has been awarded a one-year pilot project through National Heart, Lung.

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the launch of ProPhet, a new startup leveraging artificial intelligence to identify active small molecules for drug discovery.

Global pharma major Lupin Limited (Lupin) today announced its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential (GWP). This initiative aims to provide patients with pressurised

AbbVie and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology

The life science group Sartorius has published its second edition High-Throughput Screening (HTS) by Cytometry handbook. This handbook is designed to empower both new and seasoned flow cytometry users who are curious about the unique capabilities of HTS cytometry. Those using traditional systems will learn

The third-generation oral breast cancer new drug, AND019, independently developed by Kind Pharmaceuticals LLC has received IND approval by the US FDA. This is a second innovative drug approved for clinical development